

12-27-05

JRW 1647

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/010942-Conf. #5594	
	Filing Date	December 6, 2001	
	First Named Inventor	Guriq BASI	
	Art Unit	1647	
	Examiner Name	C. J. Nichols	
Total Number of Pages in This Submission		Attorney Docket Number	ELN-002

ENCLOSURES (Check all that apply)

<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Receipt Postcard
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	LAHIVE & COCKFIELD, LLP		
Signature			
Printed name	Debra J. Milasincic		
Date	December 22, 2005	Reg. No.	46,931



LAHIVE
&
COCKFIELD
L L P

COUNSELLORS AT LAW
28 STATE STREET
BOSTON, MASSACHUSETTS 02109-1784
TELEPHONE (617) 227-7400
FAX (617) 742-4214
www.lahive.com
lc@lahive.com

JOHN A. LAHIVE, JR. (1928-1997)
JAMES E. COCKFIELD (1930-2005)
THOMAS V. SMURZYNSKI
GIULIO A. DeCONTI, JR.
ELIZABETH A. HANLEY
AMY BAKER MANDRAGOURAS
ANTHONY A. LAURENTANO
KEVIN J. CANNING
JANE E. REMILLARD
DEBRA J. MILASINCIC, Ph.D.
MEGAN E. WILLIAMS, Ph.D.
WILLIAM A. SCOFIELD, JR.
SIBLEY P. REPPERT
DAVID R. BURNS
JOHN S. CURRAN
SEAN D. DETWEILER
HATHAWAY P. RUSSELL *
MARIA LACCOTRIPE ZACHARAKIS, Ph.D.
DANIELLE L. HERRITT

EUIHOON LEE **
MANEESH GULATI
CYNTHIA M. SOROOS
PETER W. DINI, Ph.D.
MICHAEL J. BASTIAN, Ph.D.
JAMES M. MCKENZIE
JILL R. GORNY
SAPNA MEHTANI, Ph.D.
CATHERINE M. BISHOP
JACOB G. WEINTRAUB
LAURA C. DILORENZO

OF COUNSEL
JEREMIAH LYNCH
JEANNE M. DIGIORGIO
CYNTHIA L. KANIK, Ph.D.
BENEDICT A. MONACHINO

PATENT AGENTS
CRISTIN HOWLEY COWLES, Ph.D.
JILL ANN MELLO, Ph.D.
CHRISTOPHER E. DRABIK
JAMES H. VELEMA
BRIAN C. TRINQUE, Ph.D.

TECHNICAL SPECIALISTS
DEBORAH L. NAGLE, Ph.D.
ANNE JACQUELINE WIZEMAN, Ph.D.
CHRISTOPHER R. COWLES, Ph.D.
W. ELANA WANG
MEAGHAN L. RICHMOND, Ph.D.
SHARON M. WALKER, Ph.D.
ALISSA H. FARIS
SEAN R. MACDAVITT

* Admitted in TX only
** Admitted in CT only

December 22, 2005

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Re: U.S. Patent Application No.: 10/010,942
For: *HUMANIZED ANTIBODIES THAT RECOGNIZE BETA AMYLOID PEPTIDE*
Inventors: Guriq Basi *et al.*
Filed: December 6, 2001
Our Ref. No.: ELN-002

Dear Sir:


I enclose herewith for filing in the above-identified application the following:

1. Supplemental Information Disclosure Statement;
2. Form PTO SB/08B;
3. PTO/SB/21;
4. Fee Transmittal
5. Copies of references cited in PTO Form PTO/SB/08B (65 references); and
6. A Return Postcard.

Please charge \$180.00 to our Deposit Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.

Express Mail Label No. EV 418604498 US

Respectfully submitted,
LAHIVE & COCKFIELD, LLP


Debra J. Milasincic, Esq.
Registration No. 46,931
Attorney for Applicants

BEST AVAILABLE COPY




Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/17 (10-02)
Approved for use through 10/31/2002. OMB 0651-0032

FEE TRANSMITTAL for FY 2005 <small>Patent fees are subject to annual revision.</small>		Complete if Known		
		Application Number	10/010942-Conf. #5594	
		Filing Date	December 6, 2001	
		First Named Inventor	Guriq BASI	
		Examiner Name	C. J. Nichols	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27		Group Art Unit	1647	
TOTAL AMOUNT OF PAYMENT (\$)		180.00	Attorney Docket No.	ELN-002

METHOD OF PAYMENT (check all that apply)		FEE CALCULATION (continued)																																																																																																																																																																																														
<input type="checkbox"/> Check	<input type="checkbox"/> CREDIT CARD	<input type="checkbox"/> MONEY ORDER	<input type="checkbox"/> OTHER	<input type="checkbox"/> NONE	3. ADDITIONAL FEES																																																																																																																																																																																											
<input checked="" type="checkbox"/> Deposit Account																																																																																																																																																																																																
Deposit Account Number: 12-0080																																																																																																																																																																																																
Deposit Account Name: Lahive & Cockfield, LLP																																																																																																																																																																																																
The Commissioner is hereby authorized to: (check all that apply)																																																																																																																																																																																																
<input checked="" type="checkbox"/> Charge fee(s) indicated below																																																																																																																																																																																																
<input checked="" type="checkbox"/> Credit any overpayments																																																																																																																																																																																																
<input type="checkbox"/> Charge any additional fee(s) during the pendency of this application																																																																																																																																																																																																
<input type="checkbox"/> Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.																																																																																																																																																																																																
FEE CALCULATION																																																																																																																																																																																																
1. BASIC FILING FEE																																																																																																																																																																																																
<table border="1"><thead><tr><th>Large Entity</th><th>Small Entity</th><th>Fee Code</th><th>Fee (\$)</th><th>Fee Description</th><th>Fee Paid</th></tr></thead><tbody><tr><td></td><td></td><td>1001</td><td>750</td><td>2001 375 Utility filing fee</td><td></td></tr><tr><td></td><td></td><td>1002</td><td>330</td><td>2002 165 Design filing fee</td><td></td></tr><tr><td></td><td></td><td>1003</td><td>520</td><td>2003 260 Plant filing fee</td><td></td></tr><tr><td></td><td></td><td>1004</td><td>750</td><td>2004 375 Reissue filing fee</td><td></td></tr><tr><td></td><td></td><td>1005</td><td>160</td><td>2005 80 Provisional filing fee</td><td></td></tr><tr><td colspan="5">SUBTOTAL (1)</td><td>(\$)</td></tr></tbody></table>						Large Entity	Small Entity	Fee Code	Fee (\$)	Fee Description	Fee Paid			1001	750	2001 375 Utility filing fee				1002	330	2002 165 Design filing fee				1003	520	2003 260 Plant filing fee				1004	750	2004 375 Reissue filing fee				1005	160	2005 80 Provisional filing fee		SUBTOTAL (1)					(\$)																																																																																																																																																	
Large Entity	Small Entity	Fee Code	Fee (\$)	Fee Description	Fee Paid																																																																																																																																																																																											
		1001	750	2001 375 Utility filing fee																																																																																																																																																																																												
		1002	330	2002 165 Design filing fee																																																																																																																																																																																												
		1003	520	2003 260 Plant filing fee																																																																																																																																																																																												
		1004	750	2004 375 Reissue filing fee																																																																																																																																																																																												
		1005	160	2005 80 Provisional filing fee																																																																																																																																																																																												
SUBTOTAL (1)					(\$)																																																																																																																																																																																											
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE																																																																																																																																																																																																
<table border="1"><thead><tr><th>Large Entity</th><th>Small Entity</th><th>Fee Code</th><th>Fee (\$)</th><th>Fee Description</th><th>Fee Paid</th></tr></thead><tbody><tr><td></td><td></td><td>1202</td><td>18</td><td>2202 9 Claims in excess of 20</td><td></td></tr><tr><td></td><td></td><td>1201</td><td>84</td><td>2201 42 Independent claims in excess of 3</td><td></td></tr><tr><td></td><td></td><td>1203</td><td>280</td><td>2203 140 Multiple dependent claim, if not paid</td><td></td></tr><tr><td></td><td></td><td>1204</td><td>84</td><td>2204 42 Reissue independent claims over original patent</td><td></td></tr><tr><td></td><td></td><td>1205</td><td>18</td><td>2205 9 Reissue claims in excess of 20 and over original patent</td><td></td></tr><tr><td colspan="5">SUBTOTAL (2)</td><td>(\$)</td></tr></tbody></table>						Large Entity	Small Entity	Fee Code	Fee (\$)	Fee Description	Fee Paid			1202	18	2202 9 Claims in excess of 20				1201	84	2201 42 Independent claims in excess of 3				1203	280	2203 140 Multiple dependent claim, if not paid				1204	84	2204 42 Reissue independent claims over original patent				1205	18	2205 9 Reissue claims in excess of 20 and over original patent		SUBTOTAL (2)					(\$)																																																																																																																																																	
Large Entity	Small Entity	Fee Code	Fee (\$)	Fee Description	Fee Paid																																																																																																																																																																																											
		1202	18	2202 9 Claims in excess of 20																																																																																																																																																																																												
		1201	84	2201 42 Independent claims in excess of 3																																																																																																																																																																																												
		1203	280	2203 140 Multiple dependent claim, if not paid																																																																																																																																																																																												
		1204	84	2204 42 Reissue independent claims over original patent																																																																																																																																																																																												
		1205	18	2205 9 Reissue claims in excess of 20 and over original patent																																																																																																																																																																																												
SUBTOTAL (2)					(\$)																																																																																																																																																																																											
3. ADDITIONAL FEES																																																																																																																																																																																																
<table border="1"><thead><tr><th>Large Entity</th><th>Small Entity</th><th>Fee Code</th><th>Fee (\$)</th><th>Fee Description</th><th>Fee Paid</th></tr></thead><tbody><tr><td></td><td></td><td>1051</td><td>130</td><td>2051 65 Surcharge - late filing fee or oath</td><td></td></tr><tr><td></td><td></td><td>1052</td><td>50</td><td>2052 25 Surcharge - late provisional filing fee or cover sheet</td><td></td></tr><tr><td></td><td></td><td>1053</td><td>130</td><td>1053 130 Non-English specification</td><td></td></tr><tr><td></td><td></td><td>1812</td><td>2,520</td><td>1812 2,520 For filing a request for ex parte reexamination</td><td></td></tr><tr><td></td><td></td><td>1804</td><td>920*</td><td>1804 920* Requesting publication of SIR prior to Examiner action</td><td></td></tr><tr><td></td><td></td><td>1805</td><td>1,840*</td><td>1805 1,840* REQUESTING PUBLICATION OF SIR AFTER</td><td></td></tr><tr><td></td><td></td><td>1251</td><td>110</td><td>2251 55 Extension for reply within first month</td><td></td></tr><tr><td></td><td></td><td>1252</td><td>410</td><td>2252 205 Extension for reply within second month</td><td></td></tr><tr><td></td><td></td><td>1253</td><td>930</td><td>2253 465 Extension for reply within third month</td><td></td></tr><tr><td></td><td></td><td>1254</td><td>1,450</td><td>2254 725 Extension for reply within fourth month</td><td></td></tr><tr><td></td><td></td><td>1255</td><td>1,970</td><td>2255 985 Extension for reply within fifth month</td><td></td></tr><tr><td></td><td></td><td>1401</td><td>320</td><td>2401 160 Notice of Appeal</td><td></td></tr><tr><td></td><td></td><td>1402</td><td>320</td><td>2402 160 Filing a brief in support of an appeal</td><td></td></tr><tr><td></td><td></td><td>1403</td><td>280</td><td>2403 140 Request for oral hearing</td><td></td></tr><tr><td></td><td></td><td>1451</td><td>1,510</td><td>1451 1,510 Petition to institute a public use proceeding</td><td></td></tr><tr><td></td><td></td><td>1452</td><td>110</td><td>2452 55 Petition to revive - unavoidable</td><td></td></tr><tr><td></td><td></td><td>1453</td><td>1,300</td><td>2453 650 Petition to revive - unintentional</td><td></td></tr><tr><td></td><td></td><td>1501</td><td>1,300</td><td>2501 650 Utility issue fee (or reissue)</td><td></td></tr><tr><td></td><td></td><td>1502</td><td>470</td><td>2502 235 Design issue fee</td><td></td></tr><tr><td></td><td></td><td>1503</td><td>630</td><td>2503 315 Plant issue fee</td><td></td></tr><tr><td></td><td></td><td>1460</td><td>130</td><td>1460 130 Petitions to the Commissioner</td><td></td></tr><tr><td></td><td></td><td>1807</td><td>50</td><td>1807 50 Processing fee under 37 CFR 1.17(q)</td><td></td></tr><tr><td></td><td></td><td>1806</td><td>180</td><td>1806 180 Submission of Information Disclosure Stmt</td><td>180.00</td></tr><tr><td></td><td></td><td>8021</td><td>40</td><td>8021 40 Recording each patent assignment per property (times number of properties)</td><td></td></tr><tr><td></td><td></td><td>1809</td><td>750</td><td>2809 375 Filing a submission after final rejection (37 CFR 1.129(a))</td><td></td></tr><tr><td></td><td></td><td>1810</td><td>750</td><td>2810 375 For each additional invention to be examined (37CFR 1.129(b))</td><td></td></tr><tr><td></td><td></td><td>1801</td><td>750</td><td>2801 375 Request for Continued Examination (RCE)</td><td></td></tr><tr><td></td><td></td><td>1802</td><td>900</td><td>1802 900 Request for expedited examination of a design application</td><td></td></tr><tr><td></td><td></td><td colspan="4">Other fee (specify) 1806 Submission of an Information Disclosure Statement</td><td>180.00</td></tr><tr><td colspan="5">*Reduced by Basic Filing Fee Paid</td><td>SUBTOTAL (3) (\$)</td></tr></tbody></table>						Large Entity	Small Entity	Fee Code	Fee (\$)	Fee Description	Fee Paid			1051	130	2051 65 Surcharge - late filing fee or oath				1052	50	2052 25 Surcharge - late provisional filing fee or cover sheet				1053	130	1053 130 Non-English specification				1812	2,520	1812 2,520 For filing a request for ex parte reexamination				1804	920*	1804 920* Requesting publication of SIR prior to Examiner action				1805	1,840*	1805 1,840* REQUESTING PUBLICATION OF SIR AFTER				1251	110	2251 55 Extension for reply within first month				1252	410	2252 205 Extension for reply within second month				1253	930	2253 465 Extension for reply within third month				1254	1,450	2254 725 Extension for reply within fourth month				1255	1,970	2255 985 Extension for reply within fifth month				1401	320	2401 160 Notice of Appeal				1402	320	2402 160 Filing a brief in support of an appeal				1403	280	2403 140 Request for oral hearing				1451	1,510	1451 1,510 Petition to institute a public use proceeding				1452	110	2452 55 Petition to revive - unavoidable				1453	1,300	2453 650 Petition to revive - unintentional				1501	1,300	2501 650 Utility issue fee (or reissue)				1502	470	2502 235 Design issue fee				1503	630	2503 315 Plant issue fee				1460	130	1460 130 Petitions to the Commissioner				1807	50	1807 50 Processing fee under 37 CFR 1.17(q)				1806	180	1806 180 Submission of Information Disclosure Stmt	180.00			8021	40	8021 40 Recording each patent assignment per property (times number of properties)				1809	750	2809 375 Filing a submission after final rejection (37 CFR 1.129(a))				1810	750	2810 375 For each additional invention to be examined (37CFR 1.129(b))				1801	750	2801 375 Request for Continued Examination (RCE)				1802	900	1802 900 Request for expedited examination of a design application				Other fee (specify) 1806 Submission of an Information Disclosure Statement				180.00	*Reduced by Basic Filing Fee Paid					SUBTOTAL (3) (\$)
Large Entity	Small Entity	Fee Code	Fee (\$)	Fee Description	Fee Paid																																																																																																																																																																																											
		1051	130	2051 65 Surcharge - late filing fee or oath																																																																																																																																																																																												
		1052	50	2052 25 Surcharge - late provisional filing fee or cover sheet																																																																																																																																																																																												
		1053	130	1053 130 Non-English specification																																																																																																																																																																																												
		1812	2,520	1812 2,520 For filing a request for ex parte reexamination																																																																																																																																																																																												
		1804	920*	1804 920* Requesting publication of SIR prior to Examiner action																																																																																																																																																																																												
		1805	1,840*	1805 1,840* REQUESTING PUBLICATION OF SIR AFTER																																																																																																																																																																																												
		1251	110	2251 55 Extension for reply within first month																																																																																																																																																																																												
		1252	410	2252 205 Extension for reply within second month																																																																																																																																																																																												
		1253	930	2253 465 Extension for reply within third month																																																																																																																																																																																												
		1254	1,450	2254 725 Extension for reply within fourth month																																																																																																																																																																																												
		1255	1,970	2255 985 Extension for reply within fifth month																																																																																																																																																																																												
		1401	320	2401 160 Notice of Appeal																																																																																																																																																																																												
		1402	320	2402 160 Filing a brief in support of an appeal																																																																																																																																																																																												
		1403	280	2403 140 Request for oral hearing																																																																																																																																																																																												
		1451	1,510	1451 1,510 Petition to institute a public use proceeding																																																																																																																																																																																												
		1452	110	2452 55 Petition to revive - unavoidable																																																																																																																																																																																												
		1453	1,300	2453 650 Petition to revive - unintentional																																																																																																																																																																																												
		1501	1,300	2501 650 Utility issue fee (or reissue)																																																																																																																																																																																												
		1502	470	2502 235 Design issue fee																																																																																																																																																																																												
		1503	630	2503 315 Plant issue fee																																																																																																																																																																																												
		1460	130	1460 130 Petitions to the Commissioner																																																																																																																																																																																												
		1807	50	1807 50 Processing fee under 37 CFR 1.17(q)																																																																																																																																																																																												
		1806	180	1806 180 Submission of Information Disclosure Stmt	180.00																																																																																																																																																																																											
		8021	40	8021 40 Recording each patent assignment per property (times number of properties)																																																																																																																																																																																												
		1809	750	2809 375 Filing a submission after final rejection (37 CFR 1.129(a))																																																																																																																																																																																												
		1810	750	2810 375 For each additional invention to be examined (37CFR 1.129(b))																																																																																																																																																																																												
		1801	750	2801 375 Request for Continued Examination (RCE)																																																																																																																																																																																												
		1802	900	1802 900 Request for expedited examination of a design application																																																																																																																																																																																												
		Other fee (specify) 1806 Submission of an Information Disclosure Statement				180.00																																																																																																																																																																																										
*Reduced by Basic Filing Fee Paid					SUBTOTAL (3) (\$)																																																																																																																																																																																											
SUBMITTED BY																																																																																																																																																																																																
Name (Print/Type) Debra J. Milasincic																																																																																																																																																																																																
Registration No. (Attorney/Agent) 46,931																																																																																																																																																																																																
Telephone (617) 227-7400																																																																																																																																																																																																
Signature																																																																																																																																																																																																
Date December 22, 2005																																																																																																																																																																																																

Express Mail Label No. EV 418604498 US Dated: December 22, 2005



Express Mail Label No. EV 418604498 US

Dated: December 22, 2005

Docket No.: ELN-002
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inter Patent Application of:
Guriq Basi *et al.*

Application No.: 10/010942

Confirmation No.: 5594

Filed: December 6, 2001

Art Unit: 1649

For: HUMANIZED ANTIBODIES THAT
RECOGNIZE BETA AMYLOID PEPTIDE

Examiner: K. A. Ballard

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicant(s) and their Attorney are aware of the following publications, listed on the attached PTO Form SB/08, and in accordance with 37 CFR 1.97 hereby submit these publications for the Examiner's consideration. A copy of each cited publication is enclosed.

Applicant also cites commonly owned copending applications directed to related subject matter:

09/201,430 filed 11/30/98 issued as U.S. 6,787,523 on 09/07/04;
09/497,553 filed 02/03/00;
09/724,477 filed 11/28/00 issued as U.S. 6,787,143 on 09/07/04;
09/723,927 filed 11/28/00 issued as U.S. 6,787,138 on 09/07/04;
09/723,762 filed 11/28/00 issued as U.S. 6,787,144 on 09/07/04;
09/724,102 filed 11/28/00 issued as U.S. 6,787,139 on 09/07/04;
09/724,489 filed 11/28/00 issued as U.S. 6,787,140 on 09/07/04;
10/816,022 filed 03/31/04 issued as U.S. 6,866,850 on 03/15/05;
10/816,529 filed 03/31/04 issued as U.S. 6,818,218 on 11/16/04;

12/30/2005 DTESSEM1 00000003 120080 10010942

01 FC:1806 180.00 DA

10/815,391 filed 03/31/04 issued as U.S. 6,866,849 on 03/15/05;
10/934,818 filed 09/02/04;
10/934,609 filed 09/02/04 issued as U.S. 6,946,135 on 09/20/2005;
10/933,559 filed 09/02/04 issue fee paid 01/24/05;
10/934,819 filed 09/02/04;
10/815,353 filed 03/31/04 issued as U.S. 6,808,712 on 10/26/04;
10/816,380 filed 03/31/04 issue fee paid 01/24/05;
10/815,404 filed 03/31/04 issue fee paid 11/12/04;
10/884,892 filed 07/01/04 issued as U.S. 6,962,707 on 11/08/05
09/322,289 filed 05/28/99;
09/723,713 filed 11/27/00;
09/723,760 filed 11/27/00;
09/724,319 filed 11/27/00;
09/723,384 filed 11/27/00 issued as U.S. 6,710,226 on 03/23/04;
09/724,495 filed 11/27/00;
10/788,666 filed 02/27/04;
10/429,216 filed 05/30/03;
10/828,548 filed 04/19/04;
10/923,471 filed 08/20/04;
10/923,474 filed 08/20/04;
10/928,926 filed 08/27/04;
10/923,605 filed 08/20/04;
10/923,267 filed 08/20/04;
10/923,469 filed 08/20/04;
09/580,015 filed 05/26/00;
09/724,940 filed 11/28/00 issued as U.S. 6,905,686 on 06/14/05;
09/724,961 filed 11/28/00 issued as U.S. 6,743,427 on 06/01/04;
09/580,018 filed 05/26/00 issued as U.S. 6,761,888 on 07/13/04;
09/724,552 filed 11/28/00 issued as U.S. 6,750,324 on 06/15/04;
09/723,544 filed 11/28/00;
09/724,273 filed 11/28/00;
09/724,551 filed 11/28/00 issued as U.S. 6,787,637 on 09/07/04;

09/724,288 filed 11/28/00;
10/777,792 filed 02/11/04;
10/890,024 filed 04/12/04;
10/889,999 filed 04/12/04;
10/890,000 filed 07/12/04;
10/890,070 filed 07/12/04;
10/890,071 filed 07/12/04;
09/580,019 filed 05/26/00;
09/723,765 filed 11/28/00;
09/724,291 filed 11/28/00;
10/822,968 filed 04/12/04;
09/724,929 filed 11/28/00;
09/724,567 filed 11/28/00 issued as U.S. 6,890,535 on 05/10/05;
09/724,575 filed 11/28/00;
09/724,953 filed 11/28/00 issued as U.S. 6,875,434 on 04/05/05;
09/724,570 filed 11/28/00 issue fee paid 02/10/05;
09/585,656 filed 06/01/00;
09/723,766 filed 11/27/00;
09/723,725 filed 11/27/00;
09/579,690 filed 05/26/00;
09/979,701 filed 03/13/01 (U.S. Nat'l Stage of PCT/US00/14810 filed 05/26/00);
09/979,952 filed 04/09/02 (U.S. Nat'l Stage of PCT/US00/15239 filed 06/01/00);
issued as U.S. 6,913,745 on 07/05/05; and,
09/980,568 filed 03/12/02 (U.S. Nat'l Stage of PCT/US00/15302 filed 06/01/00).

Applicant also cites the following copending applications directed to related subject matter but subject to different assignment:

10/010,942 filed 12/06/01;
10/789,273 filed 02/27/04;
10/232,030 filed 08/30/02;
10/010,942 filed 12/06/01;
10/388,389 filed 03/12/03;

10/703,713 filed 11/07/03;
10/704,070 filed 11/07/03;
10/388,214 filed 03/12/03;
10/858,855 filed 06/01/04;
10/771,174 filed 02/04/04.
60/622,525 filed 10/26/04;
60/636,684 filed 12/15/04;
60/636,842 filed 12/15/04;
60/637,253 filed 12/16/04;
60/636,810 filed 12/15/04;
60/637,138 filed 12/16/04;
60/636,776 filed 12/15/04;
60/636,687 filed 12/15/04.

Applicant further cites the following commonly owned abandoned applications directed to related subject matter:

60/067,740 filed 12/02/97;
60/080,970 filed 04/07/98;
60/067,219 filed 12/03/97;
60/079,697 filed 03/27/98;
09/204,838 filed 12/03/98;
09/724,921 filed 11/28/00;
09/724,929 filed 11/28/00;
60/137,010 filed 06/01/99;
60/251,892 filed 12/06/00;
60/137,047 filed 06/01/99;
60/136,655 filed 05/28/99; and
09/723,544 filed 11/28/00.

Applicant also cites the following abandoned application directed to related subject matter but subject to different assignment:

60/251,892 filed 12/06/00;

60/474,654 filed 05/30/03;
60/530,481 filed 12/17/03;
60/444,150 filed 02/01/03; and,
60/363,751 filed 03/12/02.

Applicant points out that the following applications are now commonly assigned but were previously subject to different assignment than the present application:

60/067,219 filed 12/03/97;
60/079,697 filed 03/27/98;
09/204,838 filed 12/03/98;
09/724,921 filed 11/28/00; and,
09/724,929 filed 11/28/00.

Applicant understands the Examiner can access papers from the prosecution of the cited cases electronically via PALM. However, if the Examiner has difficulty obtaining papers from that source he or she is invited to call the undersigned who will be happy to supply them.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicant(s) understand(s) that the Examiner will make an independent evaluation of the cited publications.


Application No.: 10/010942

Docket No.: ELN-002


In accordance with 37 CFR §1.97(c)(2) and §1.17(p), please charge the \$180.00 submission fee to our Deposit Order Account No. 12-0080. Please charge any necessary additional fees or credit any overpayments to our Deposit Order Account No. 12-0080.

Dated: December 22, 2005

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Debra J. Milasincic', is written over a horizontal line. The signature is fluid and cursive, with a large loop at the beginning and several sharp peaks and valleys.

By
Debra J. Milasincic
Registration No.: 46,931
LAHIVE & COCKFIELD, LLP
28 State Street
Boston, Massachusetts 02109
(617) 227-7400
(617) 742-4214 (Fax)
Attorney/Agent For Applicant



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/010,942
Filing Date	December 6, 2001
First Named Inventor	Guriq Basi, et al.
Art Unit	1649
Examiner Name	Ballard, Kimberly A.
Attorney Docket Number	ELN-002

Sheet 1 of 6

U.S. PATENT DOCUMENTS

Examiner	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	679	2005/0255122 A1	11-17-2005	Schenk	
	680	2005/0249727 A1	11-10-2005	Schenk	
	674	6,962,707	11-08-2005	Schenk	
	656	6,946,135	09-20-2005	Schenk	
	657	6,913,745	07-05-2005	Schenk	
	658	6,905,686	06-14-2005	Schenk	
	659	6,890,535	05-10-2005	Schenk	
	661	2005/0009150 A1	01-13-2005	Basi et al.	
	583	2004/0265919 A1	12-30-2004	Vanderstichlele et al.	
	581	2004/0247612 A1	12-09-2004	Wang	
	582	2004/0241164 A1	12-02-2004	Bales et al.	
	673	6,808,712	10-26-2004	Schenk	
	667	6,787,523	09-07-2004	Schenk	
	670	6,787,144	09-07-2004	Schenk	
	668	6,787,143	09-07-2004	Schenk	
	672	6,787,140	09-07-2004	Schenk	
	669	6,787,138	09-07-2004	Schenk	
	671	6,787,129	09-07-2004	Schenk	
	660	2004/0171815 A1	09-02-2004	Schenk et al.	
	675	6,710,226	02-23-2004	Schenk	
	584	5,589,154	12-31-1996	Anderson	
	644	5,618,920	04-08-1997	Robinson et al.	
	643	5,693,762	12-02-1997	Queen et al.	
	642	5,702,906	12-30-1997	Rosenthal	
	646	4,816,567	03-28-2989	Cabilly et al.	
	645	5,258,498	11-02-1993	Huston et al.	
	647	4,816,397	03-28-1989	Boss et al.	

FOREIGN PATENT DOCUMENTS


Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD- YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	587	JP	7-165799	A	06-27-1995			abst. only

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 60284284 v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/010,942
				Filing Date	December 6, 2001
				First Named Inventor	Guriq Basi, et al.
				Art Unit	1649
				Examiner Name	Ballard, Kimberly A.
Sheet 2 of 6	Attorney Docket Number	ELN-002			

	632	JP	7-132033	A	05-23-1995		abst. only
	631	JP	62-267297	A	11-19-1987		abst. only
	585	WO	04/080419	A2	09-23-2004		
	586	WO	03/077858	A2, A3	09-25-2003		
	633	WO	96/08565	A2	03-21-1996		
	630	WO	95/17085	A1	06-29-1995		
	648	WO	91/09967	A1	07-11-1991		

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS


Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	663	ALBERTS et al., eds. <i>Molecular Biology of The Cell, Third Edition</i> , chapter 23, pages 1208-1209 (1994).	
	649	AMIT et al., "Three-Dimensional Structure of an Antigen-Antibody Complex at 2.8 Å Resolution," <i>Science</i> , 233:747-753 (1986).	
	588	ANDERSON, J. P., "Exact cleavage site of Alzheimer amyloid precursor in neuronal PC-12 cells," <i>Neuroscience Letters</i> , 128(1):126-128 (1991).	
	589	ANDERSON, M. W., "Amending the amyloid hypothesis," <i>The Scientist</i> , 18(20):28-29 (2004).	
	677	ANKARCRONA et al., "Biomarkers for apoptosis in Alzheimer's disease," <i>Int. J. Geriatric Psychiatry</i> , 20:101-105 (2005).	
	590	BACSKAI et al., "Non-Fc-mediated mechanisms are involved in clearance of amyloid-β in vivo by immunotherapy," <i>J. Neurosci.</i> , 22(18):7873-7878 (2002).	
	639	Chimicon International, "Mouse Anti-Amyloid Beta Protein Monoclonal Antibody," Catalog # MAB1561	
	591	CHROMY et al., "Self-assembly of Aβ(1-42) into globular neurotoxins," <i>Biochemistry</i> , 42(44):12749-12760 (2003).	
	592	CITRON et al., "Evidence that the 42- and 40- amino acid forms of amyloid-β protein are generated from the β-amyloid precursor protein by different protease activities," <i>PNAS</i> , 93(23):13170-13175 (1996).	
	593	CITRON, M., "Alzheimer's disease: treatments in discovery and development," <i>Nat. Neurosci.</i> , 5:1055-1057 (2002).	
	594	DEMATTOIS et al., "Brain to plasma amyloid-β efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease," <i>Science</i> , 295(5563):2264-2267 (2002).	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60284284 v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 6

Complete if Known

Application Number	10/010,942
Filing Date	December 6, 2001
First Named Inventor	Guriq Basi, et al.
Art Unit	1649
Examiner Name	Ballard, Kimberly A.
Attorney Docket Number	ELN-002

595	DODART et al., "Immunization reverses memory deficits without reducing brain A β burden in Alzheimer's disease model," <u>Nat. Neurosci.</u> , 5(5):452-457 (2002).
596	DODEL et al., "Immunotherapy for Alzheimer's disease," <u>Lancet Neurol.</u> , 2(4):215-220 (2003).
597	DOVEY et al., "Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain," <u>J. Neurochem.</u> , 76(1):173-181 (2001).
598	DUFF et al., "Increased amyloid- β 42(43) in brains of mice expressing mutant presenilin 1," <u>Nature</u> , 383(6602):710-713 (1996).
599	ERIKSEN et al., "NSAIDs and enantiomers of flurbiprofen target γ -secretase and lower A β 42 in vivo," <u>J. Clin. Invest.</u> , 112(3):440-449 (2003).
600	FINDEIS, M. A., "Approaches to discovery and characterization of inhibitors of amyloid β -peptide polymerization," <u>Biochem. Biophys. Acta</u> , 1502(1):76-84 (2000).
650	FOOTE et al., "Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops," <u>J. Mol. Biol.</u> , 224:487-499 (1992).
601	FRENKEL et al., "Reduction of β -amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization," <u>Vaccine</u> , 21(11-12):1060-1065 (2003).
602	FRENKEL et al., "Towards Alzheimer's β -amyloid vaccination," <u>Biologicals</u> , 29(3-4):243-247 (2001).
603	GELINAS et al., "Immunotherapy for Alzheimer's disease," <u>PNAS</u> , 101(suppl. 2):14657-14662 (2004).
604	GONG et al., "Alzheimer's disease-affected brain: presence of oligomeric A β ligands (ADDLs) suggests a molecular basis for reversible memory loss," <u>PNAS</u> , 100(18):10417-10422 (2003).
605	GREENBERG et al., "Alzheimer disease's double-edged vaccine," <u>Nat. Med.</u> , 9(4):389-390 (2003).
606	HAASS, C., "New hope for Alzheimer disease vaccine," <u>Nat Med.</u> , 8(11):1195-1196 (2002).
664	HARLOW et al., eds., <i>Antibodies: A Laboratory Manual</i> , pages 71-82 (1998).
607	HOCK et al., "Generation of antibodies specific for β -amyloid by vaccination of patients with Alzheimer disease," <u>Nat. Med.</u> , 8(11):1270-1275 (2002).
662	IDA et al., "Analysis of Heterogeneous β A4 Peptides in Juman Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay," <u>J. Biol. Chem.</u> , 271(37):22908-22914 (1996).


Examiner
Signature

Date
Considered

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60284284 v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Institute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 6

Complete if Known

Application Number	10/010,942
Filing Date	December 6, 2001
First Named Inventor	Guriq Basi, <i>et al.</i>
Art Unit	1649
Examiner Name	Ballard, Kimberly A.
Attorney Docket Number	ELN-002

608	IRIZARRY <i>et al.</i> , "Alzheimer disease therapeutics," <u>J. Neuropathol. Exp. Neurol.</u> , 60(10):923-928 (2001).
609	JANUS <i>et al.</i> , "Transgenic mouse models of Alzheimer's Disease," <u>Physiol. Behav.</u> , 73(5):873-886 (2001).
640	JUNG <i>et al.</i> , "Alzheimer's Beta-amyloid Precursor Protein Is Expressed on the Surface of Immediately Ex Vivo Brain Cells: a Flow Cytometric Study," <u>J. Neurosci. Res.</u> , 46:336-348 (1996).
628	KOFLER <i>et al.</i> "Mechanism of allergic cross-reactions—III. cDNA cloning and variable-region sequence analysis of two IgE antibodies specific for trinitrophenyl." <u>Mol Immunol.</u> 29(2):161-6 (1992).
635	KOFLER <i>et al.</i> "IgE antibody light chain (VJ) [Mus musculus]." GenBank Accession No. CAA46659. Retrieved from the internet at http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&val=1870480 on August 26, 2005.
636	KOFLER <i>et al.</i> "M.musculus DNA for IgE antibody light chain (VJ)." GenBank Accession No. X65775. Retrieved from the internet at http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=312078 on August 26, 2005.
627	KRISHNAN <i>et al.</i> , "Correlation between the amino acid position of arginine in VH-CDR3 and specificity for native DNA among autoimmune antibodies." <u>J Immunol.</u> 157(6):2430-9 (1996).
634	KRISHNAN <i>et al.</i> "anti-DNA immunoglobulin light chain IgG [Mus musculus]." Genbank Accession No. AAB488000. Retrieved from the internet at http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&val=1870480 on 08-26-2005.
651	LANDOLFI <i>et al.</i> , "The Integrity of the Ball-and Socket Joint Between V and C Domains Is Essential for Complete Activity of a Humanized Antibody," <u>J. Immunology</u> , pages 1748-1754 (2001).
665	LO <i>et al.</i> , "High level expression and secretion of Fc-X fusion proteins in mammalian cells," <u>Protein Engineering</u> , 11(6):495-500 (1998).
666	MANDEL <i>et al.</i> , "Clinical trials in neurological disorders using AAV vectors: promises and challenges," <u>Curr. Opin. Mol. Ther.</u> , 6(5):482-490 (2004).
610	MATTSON <i>et al.</i> , "Good and bad amyloid antibodies," <u>Science</u> , 301(5641):1845-1849 (2003).
611	MCLAURIN <i>et al.</i> , "Therapeutically effective antibodies against amyloid- β peptide target amyloid- β residues and 4-10 and inhibit cytotoxicity and fibrillogenesis," <u>Nat Med.</u> , 8(11):1263-1269 (2002).
612	MONSONEGO <i>et al.</i> , "Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer's disease," <u>J. Clin. Invest.</u> , 112(3):415-422 (2003).
613	MONSONEGO <i>et al.</i> , "Immunotherapeutic approaches to Alzheimer's disease," <u>Science</u> , 302(5646):834-838 (2003).


Examiner
Signature

Date
Considered

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60284284 v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 6

Complete if Known

Application Number	10/010,942
Filing Date	December 6, 2001
First Named Inventor	Guriq Basi, et al.
Art Unit	1649
Examiner Name	Ballard, Kimberly A.
Attorney Docket Number	ELN-002

652	ORLANDI et al., "Cloning immunoglobulin variable domains for expression by the polymerase chain reaction," <u>PNAS</u> , 86:3833-3837 (1989).	
614	PAGANETTI et al., "Amyloid precursor protein truncated at any of the γ -secretase sites is not cleaved to β -amyloid," <u>J. Neurosci. Res.</u> , 46(3):283-293 (1996).	
615	PALLITTO et al., "Recognition sequence design for peptidyl modulators of β -amyloid aggregation and toxicity," <u>Biochemistry</u> , 38(12):3570-3578 (1999).	
654	PANKA et al., "Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies," <u>PNAS</u> , 85:3080-3084 (1998).	
653	PAUL, W. E., eds., <i>Fundamental Immunology</i> , Third Edition, pages 292-295, Raven Press, New York (1993).	
616	PFEIFER et al., "Cerebral hemorrhage after passive anti-A β immunotherapy," <u>Science</u> , 298(5597):1379 (2002).	
641	RACKE et al., "Exacerbation of Cerebral Amyloid Angiopathy-Associated Microhemorrhage in Amyloid Precursor Protein Transgenic Mice by Immunotherapy Is Dependent on Antibody Recognition of Deposited Forms of amyloid β ," <u>J. Neurosci.</u> , 25(3):629-636 (2005).	
638	Research Corporation Technology News, "THP and SangStat Partner to Develop Humanized Polyclonal Antibody Drugs," 11/11/02.	
626	"Researchers Develop Blood Test to Diagnose Alzheimer's- Type Changes in Mice," downloaded from www.businesswire.com on 12/15/04.	
655	RUDIHOFF et al., "Single amino acid substitution altering antigen-binding specificity," <u>PNAS</u> , 79:1979-1983 (1982).	
617	SCHMID, R. E., "Study suggest Alzheimer vaccine fix," from www.msnbc.com/news , pages 1-5 (2002).	
629	SEIDL, K.J. et al. "Predominant VH genes expressed in innate antibodies are associated with distinctive antigen-binding sites." <u>Proc Natl Acad Sci U S A</u> . 96(5):2262-7 (1999).	
637	SEIDL, K.J. et al. "immunoglobulin heavy chain VH3609-JH3 region [Mus musculus]." GenBank Accession No. AAD26773. Retrieved from the internet at http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&val=4633434 on August 26, 2005.	
618	SELKOE, D. J., "Alzheimer's disease is a synaptic failure," <u>Science</u> , 298(5594):789-791 (2002).	
622	SERGEANT et al., "Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach," <u>J. Neurochem.</u> , 85(6):1581-1591 (2003).	


Examiner
Signature

Date
Considered

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60284284 v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/010,942
		Filing Date	December 6, 2001
		First Named Inventor	Guriq Basi, et al.
		Art Unit	1649
		Examiner Name	Ballard, Kimberly A.
Sheet 6 of 6	Attorney Docket Number	ELN-002	

619	SIGURDSSON et al., "Immunization with a nontoxic/nonfibrillar amyloid- β homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice," <u>Am. J. Pathol.</u> , 159(2):439-447 (2001).	
620	SOLOMON, B., "Generation and brain delivery of anti-aggregating antibodies against β -amyloid plaques using phage display technology," <u>J. Neural Transm. Suppl.</u> , 62:321-325 (2002).	
621	SOLOMON, B., "Immunotherapeutic strategies for prevention and treatment of Alzheimer's disease," <u>DNA and Cell Biology</u> , 20(11):697-703 (2001).	
678	SOUDER et al., "Overview of Alzheimer's disease," <u>Nurs. Clin. N. Am.</u> , 39:545-559 (2004).	
623	WALSH et al., "Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo," <u>Nature</u> , 416(6880):535-539 (2002).	
624	WASHINGTON UNIVERSITY IN ST. LOUIS SCHOOL OF MEDICINE, "Study gives Clues to Working of Anti-Alzheimer Antibody," downloaded from www.medicine.wustl.edu/~wumpa/news on 12/15/04.	
676	<i>Webster's New World Dictionary</i> , page 1387, therapeutic (1988).	
625	WHITE et al., "Immunotherapy as a therapeutic treatment for neurodegenerative disorders," <u>J. Neurochem.</u> , 87(4):801-808 (2003).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60284284 v1